Inhibikase Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Inhibikase Therapeutics has filed a registration statement for the resale of up to 4,761,904 shares of common stock by a selling stockholder upon the exercise of outstanding warrants.
NASDAQ
Inhibikase Therapeutics files an amendment to its S-1 registration statement to update the legal opinion regarding its proposed public offering of common stock and warrants.
NASDAQ
Inhibikase Therapeutics plans a best-efforts public offering of common stock and warrants to raise capital for general corporate purposes.
NASDAQ
Inhibikase Therapeutics launches a best-efforts offering of common stock and warrants to fund clinical trials and biomarker programs for Parkinson's disease and Multiple System Atrophy.
NASDAQ
Inhibikase Therapeutics plans a best-efforts public offering of common stock and warrants to fund clinical trials and corporate purposes.
NASDAQ
Inhibikase Therapeutics is planning a best-efforts public offering of common stock and accompanying warrants, along with pre-funded warrants for certain investors.